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For many, the extent to which blood glucose control can be lowered is limited 
by risk of hypoglycaemia. Hypoglycaemia is feared and carries fiscal, social 
and medical costs, with risk of death being associated with severe 
hypoglycaemia in patients with type 2 diabetes at high cardiovascular risk. In 
this issue of Diabetologia, Chow et al (DOI: details to be inserted at proofs) 
report that patients with type 2 diabetes who suffered severe hypoglycaemia 
during attempts to lower blood glucose intensively were more likely to be 
insulin deficient and/or carry markers of autoimmunity more usually 
associated with type 1 diabetes. This opens the question of whether 
biomarkers might help clinicians identify those patients at greater or lower risk 
of treatment-induced hypoglycaemia, allowing therapeutic targets to be 
modified accordingly. 
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Following the publication of the UKPDS study in 1998 [1], glycaemic targets in 
type 2 diabetes seemed simple. The lower the achieved HbA1c, the better in 
terms of reducing the risk of complications. Hypoglycaemia was generally 
regarded as an inconvenient obstacle and/or an inevitable by-product of these 
attempts to lower blood glucose.  The HbA1c achieved in the intensive and 
standard arms of UKPDS were 53 mmol/mol (7.0%) and 63 mmol/mol (7.9%), 
respectively, so still above the non-diabetic range. Three large studies then 
set out to examine whether lowering HbA1c further towards the non-diabetic 
range in type 2 diabetic patients with high cardiovascular risk led to further 
reductions in complication risk. Two of these, the Action in Diabetes and 
Vascular Disease: Preterax and Diamicron Modified Release Controlled 
Evaluation (ADVANCE) and the Veterans Affairs Diabetes Trial (VADT), 
showed no benefits in terms of macrovascular disease or mortality from tight 
control [2,3]. Alarmingly, the third study, the US-based Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study showed increased mortality 
in the intensively treated group and was halted early [4].  
 
The cause(s) for this apparently paradoxical rise in mortality with tight blood 
glucose control remain unexplained. However, it was clear that more 
aggressive blood glucose lowering was associated with increased risk of 
hypoglycaemia and that there was also a robust association between severe 
hypoglycaemia—defined as episodes requiring external assistance—and risk 
of dying in the ACCORD study.  The obvious question of whether the 
relationship between severe hypoglycaemia and mortality is causal or mere 
association remains undetermined [5]. Although experimental studies in 
humans and rodents have identified potential mechanistic changes that could 
explain an association, for example, by inducing cardiac dysrhythmias [6, 7], 
infrequent fatal events are difficult to study at a population level. However, 
whether it increases the risk of dying or not, hypoglycaemia is still clinically 
important, being feared by patients as much as chronic complications, 
increasing the risk of accidents, carrying social and economic costs (e.g. 
limitations on occupation, driving) and limiting the degree to which HbA1c can 
be lowered. 
 
We already know from type 1 diabetes that a small subset of patients 
accounts for a relatively large proportion of hypoglycaemic episodes. 
Assuming that different groups of patients with type 2 diabetes—a more 
heterogeneous disease—might also show different risks, this could be of 
relevance to clinical practice. If we could predict in advance which type 2 
diabetic patients might be at higher or lower risk of hypoglycaemia, then 
treatment regimens and the degree of intensification of glycaemia could be 
individualised accordingly. In this issue of Diabetologia, Chow and colleagues 
examined a cohort of ACCORD patients for biomarkers associated with 
severe hypoglycaemia. They compared 326 cases from the ACCORD study 
who had severe hypoglycaemia despite failure to achieve HbA1c below 42 
mmol/mol (6.0%) with demographically matched (for age, race, BMI) controls 
who were able to achieve an HbA1c below 42 mmol/mol without severe 
hypoglycaemia [8]. Hypothesising that there is an association between 
hypoglycaemia and insulinopenia, Chow et al found that baseline insulin 
deficiency (fasting C-peptide ≤0.15 nmol/l) was significantly associated with 
severe hypoglycaemia (OR 23 comparing severe hypoglycaemia cases and 
non-severe hypoglycaemia controls). There were weaker but significant 
associations with presence of detectable autoantibodies more usually 
associated with type 1 diabetes (glutamic acid decarboxylase [GAD], tyrosine 
phosphatase-related islet antigen-2 [IA2], zinc transporter [ZnT8]).   
 
There are a number of potential explanations for an association between 
insulin deficiency and severe hypoglycaemia risk in type 2 diabetes. First, an 
obvious possible reason is that patients with insulin deficiency are likely to be 
treated with insulin, the most potent blood glucose-lowering therapy, with 
attendant risk of overshooting into hypoglycaemia. In addition, counter-
regulatory responses are reduced in type 2 diabetic patients with insulin 
deficiency. In health, a major counter-regulatory defence against a falling 
blood glucose is the ability of the healthy beta cell to switch off endogenous 
insulin secretion. This occurs at an early stage of hypoglycaemia as blood 
glucose falls below 4 mmol/l. Nearly 90% of the hypoglycaemia group were on 
exogenous insulin at baseline, with little or no ability to modulate circulating 
insulin as glucose levels fell. In addition to switching off insulin, the healthy 
islet will increase glucagon release in response to a falling blood glucose 
level. Glucagon counter-regulatory responses to hypoglycaemia are also 
thought to become deficient in long-standing type 2 diabetes with beta cell 
failure/ exhaustion. 
 
Approximately 10% of patients diagnosed clinically with type 2 diabetes have 
detectable islet antibodies [9, 10], a condition attracting various labels, 
including latent autoimmune diabetes in adults (LADA). The assumption here 
is that the association between severe hypoglycaemia and markers of 
autoimmunity is mediated by reduced insulin secretion. In addition to 
autoimmunity, insulin deficiency may develop with long-standing type 2 
diabetes and, consistent with this, the severe hypoglycaemia group studied 
here had longer duration of known diabetes than their demographically 
matched controls. These observations are in keeping with data reporting that 
rates of severe hypoglycaemia in long-standing type 2 diabetes are similar to 
those seen in type 1 diabetes [11]. 
 
Leaving aside the issues raised from the main ACCORD findings about what 
glycaemic targets to aim for, what are the possible implications of this work for 
clinicians and patients wanting to intensify blood glucose lowering but 
concerned about risk of hypoglycaemia? First, this confirms clinical suspicion 
that there may be ‘biological’ determinants of hypoglycaemia risk. In other 
words, even when allowing for known hypoglycaemia risk factors better 
defined in type 1 diabetes (e.g. alcohol, dose errors, missed meals, activity, 
concurrent illness, therapy concordance), there may still be intrinsic reasons 
why some groups of patients are just at higher risk of hypoglycaemia with 
intensified glucose lowering.  
 
Intriguingly, there have been reports of severe hypoglycaemia risk being 
associated with a polymorphism (D/D deletion) in ACE which encodes 
angiotensin-converting enzyme in both type 2 and type 1 diabetes [12, 13]. 
The postulated mechanism here is different from those described above, with 
molecular differences in the renin–angiotensin system determining how 
sensitive cognitive functioning is to a fall in glucose. Those carrying the DD 
ACE genotype for example are thought to be more likely to develop cognitive 
dysfunction as blood glucose falls and brain fuel supply becomes impaired. 
This means that judgement and the ability to make rational decisions about 
self-treatment of hypoglycaemia may become affected earlier and/or more 
profoundly during hypoglycaemia, increasing the chances that external 
assistance is needed for rescue. This illustrates the point that different causes 
may exist for severe hypoglycaemia risk: therapeutic, educational, 
behavioural, biological and just plain bad luck/circumstances. In large 
longitudinal studies, better phenotyping of the nature and potential drivers of 
hypoglycaemia may be needed for identification of robust biomarkers, 
perhaps allowing therapies to be targeted accordingly.  
 
Should we now be routinely measuring autoantibodies and insulin reserve in 
type 2 diabetes to predict severe hypoglycaemia risk? The answer is probably 
not, based on these data. This study was a post hoc analysis based on a 
cohort of ACCORD patients identified because of their glycaemic responses 
and did not examine the predictive value for clinicians to use these 
biomarkers to predict severe hypoglycaemia risk. Looking at the distribution of 
the biomarkers, 17% of patients experiencing severe hypoglycaemia had 
insulin deficiency, with a similar number having anti-GAD antibodies.  This 
means that 83% of patients experiencing severe hypoglycaemia would not 
have been identified by either of these measures alone. Further work is 
needed to establish the merits of screening for insulin deficiency in type 2 
diabetes, but this is an important clinical area. 
 
Individualising treatment regimens is of course already the stock trade of 
clinical teams. For example, the choice of therapy and glycaemic targets will 
probably be different in an 85-year-old with type 2 diabetes compared with a 
40-year-old patient. All of this emphasises that type 2 diabetes is a mixed bag 
and that clinical management should be individualised—an important point 
that can easily be lost with generic type 2 diabetes clinical guidelines! 
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